P53 Reactivation via MDM2 Inhibition with Milademetan: Phase 3 Data in 1H 2023 (Rain Therapeutics)

MDM2 is a key regulator of the holy grail of oncology, the tumor suppressor called p53—an intractable, as yet undruggable target. But you can drug MDM2, and a number of companies have, only to walk away due to unacceptable toxicity. The MDM2 inhibitor milademetan has solved that problem, and in doing so opened the door to treating multiple tumor types, as identified by standard molecular testing. Indeed, cancers as different as liposarcoma, and Merkle Cell are already responding to this drug. Let the Wall Street veteran, CEO Avanish Vellanki, walk you through the RAIN.